Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
RESEARCH TOOLSreports
MRVI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.94 - $11.56
Previous CloseN/A
Volume457.32K
Average Volume (3M)2.27M
Market Cap
$997.48M
Enterprise Value$1.43B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Feb 25, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding141,843,500
10 Day Avg. Volume2,490,393
30 Day Avg. Volume2,267,875
Standard Deviation0.17
R-Squared0.00047
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.72
Price to Cash Flow (P/CF)19.60
P/FCF Ratio15.00
Enterprise Value/Market Cap1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.18
Enterprise Value/Ebitda2.60
Forecast
1Y Price Target
$9.75Price Target Upside146.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Maravai Lifesciences Holdings News
---
Bulls Say, Bears Say
Bulls Say
Industry GrowthManagement reiterated confidence on the long-term industry growth drivers, pointing to non-COVID mRNA trial starts up ~29% YTD and close to ~1,500 total active mRNA programs.
Product LaunchesMRVI has launched 21 new products YTD, including custom plate-based mRNA products and CleanScribe RNA polymerase, with positive customer feedback since launch.
Bears Say
Earnings GuidanceManagement reduced 2024 adjusted EBITDA margin by ~400bps at the midpoint, attributed to lower projected revenue from higher-margin areas.
Financial PerformanceMRVI reported 3Q results below expectations, with both segments light vs. our model.
Revenue Shortfall2024 guide cut again by $15M reflecting 3Q shortfall and worse 4Q outlook.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MRVI FAQ
What was Maravai Lifesciences Holdings’s price range in the past 12 months?
Maravai Lifesciences Holdings lowest stock price was $3.94 and its highest was $11.55 in the past 12 months.
What is Maravai Lifesciences Holdings’s market cap?
Maravai Lifesciences Holdings’s market cap is $997.48M.
When is Maravai Lifesciences Holdings’s upcoming earnings report date?
Maravai Lifesciences Holdings’s upcoming earnings report date is Feb 25, 2025 which is in 3 days.
How were Maravai Lifesciences Holdings’s earnings last quarter?
Maravai Lifesciences Holdings released its earnings results on Nov 07, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.012.
Is Maravai Lifesciences Holdings overvalued?
According to Wall Street analysts Maravai Lifesciences Holdings’s price is currently Undervalued.
Does Maravai Lifesciences Holdings pay dividends?
Maravai Lifesciences Holdings does not currently pay dividends.
What is Maravai Lifesciences Holdings’s EPS estimate?
Maravai Lifesciences Holdings’s EPS estimate is -0.04.
How many shares outstanding does Maravai Lifesciences Holdings have?
Maravai Lifesciences Holdings has 141,843,500 shares outstanding.
What happened to Maravai Lifesciences Holdings’s price movement after its last earnings report?
Maravai Lifesciences Holdings reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went down -35.204%.
Which hedge fund is a major shareholder of Maravai Lifesciences Holdings?
Currently, no hedge funds are holding shares in MRVI
---
Maravai Lifesciences Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.75 (146.84% Upside)
$9.75 (146.84% Upside)
Blogger Sentiment
Bearish
MRVI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 284.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $100.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.75%
12-Months-Change
Fundamentals
Return on Equity
-51.98%
Trailing 12-Months
Asset Growth
-43.63%
Trailing 12-Months
Company Description
Maravai Lifesciences Holdings
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
---
MRVI Company Deck
---
MRVI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with notable achievements in innovation and strategic acquisitions, but faced challenges in revenue shortfalls, market softness, and a significant goodwill impairment charge. The company's strong cash position and commitment to innovation are positive, but the financial pressures and revised guidance indicate ongoing challenges.Read More>---
MRVI Revenue Breakdown
77.79% Nucleic Acid Production
22.21% Biologics Safety Testing
---
MRVI Stock 12 Month Forecast
Average Price Target
$9.75
▲(146.84% Upside)
Technical Analysis
QuidelOrtho
―
Crispr Therapeutics AG
―
Denali Therapeutics
―
Twist Bioscience
―
BioNTech SE
―
Best Analysts Covering MRVI
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-27.75%
reiterated a buy rating 7 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -27.75% per trade.
---